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ABSTRAK
Inhibisi dari renin – angiotensin – aldosteron system (RAAS) merupakan strategi kunci untuk mengatasi 
hipertensi pada penyakit jantung dan ginjal. Namun, penghambat RAAS (penghambat enzim konversi angiotensin, 
penghambat reseptor angiotensin, penghambat reseptor aldosteron, dan penghambat renin) meningkatkan resiko 
hiperkalemia (kadar kalium serum > 5.5 mmol/L). Hal ini menimbulkan tantangan karena kelompok pasien 
dengan hiperkalemia ini membutuhkan terapi khusus. Pertimbangan untuk menginisiasi ACEI atau ARB dengan 
melihat estimasi laju filtrasi glomerulus, konsentrasi kalium basal dan melihat asupan kalium yang berlebihan, 
suplemen atau obat yang dapat meningkatkan kalium menjadi penting. Pemeriksaan kalium setelah inisiasi 
terapi dapat mencegah terjadinya hiperkalemia. Bila hiperkalemia terjadi, pengenalan terhadap disritmia 
kardiak dan terapi antagonis dari efek potassium terhadap jantung, meredistribusi kalium ke dalam sel, dan 
mengeluarkan kelebihan kalium perlu segera dilakukan. Pengetahuan dan kewaspadaan serta monitoring akan 
pemberian ACEI dan ARB terutama pada gagal ginjal kronis dapat meminimalisiasi kejadian hiperkalemia.
Kata kunci: hiperkalemia, penghambat enzim konversi angiotensin, penghambat reseptor angiotensin, 
gagal ginjal kronis.
ABSTRACT
Inhibition of the renin-angiotensin-aldosterone system (RAAS) is a key strategy in treating hypertension 
in cardiovascular and renal diseases. However, RAAS inhibitors (angiotensin-converting enzyme inhibitors, 
angiotensin receptor blockers, aldosterone receptor antagonists, and direct renin inhibitors) increase the risk 
of hyperkalemia (serum potassium >5.5 mmol/L). This poses a therapeutic challenge because these patient 
groups comprise in whom the drugs are therapeutically indicated. Important considerations when initiating 
ACEI or ARB therapy include obtaining an estimate of glomerular filtration rate and a baseline serum potassium 
concentration, as well as assessing whether the patient has excessive potassium intake from diet, supplements, 
or drugs that can also increase serum potassium. Serum potassium monitoring shortly after initiation of therapy 
can assist in preventing hyperkalemia. If hyperkalemia does develop, prompt recognition of cardiac dysrhythmias 
and effective treatment to antagonize the cardiac effects of potassium, redistribute potassium into cells, and 
remove excess potassium from the body is important. Understanding the mechanism of action and monitoring 
of ACEI and ARB coupled with judicious drug use and clinical vigilance can minimize the risk to the patient 
of developing hyperkalemia.
Keywords: hyperkalemia, angiotensin converting enzyme inhibitor, angiotensin receptor blocker, chronic 
kidney disesase.
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INTRODUCTION
Angiotensin-converting enzyme inhibitors 
(ACEI) and angiotensin receptor blockers 
(ARB) are used to lower blood pressure, treat 
heart failure, decrease cardiovascular morbidity 
and death after myocardial infarction, blunt 
progression of renal disease in non diabetic 
patients with chronic kidney disease (CKD), 
and slow renal disease progression in patients 
with type 2 diabetes.1 ACEIs and ARBs have 
shown efficacy in decreasing proteinuria, and 
slowing the progression of diabetic nephropathy. 
Their use, however, is sometimes complicated 
by hyperkalemia that may necessitate their 
discontinuation.2
The use of ACEI/ARB in patients with 
advanced renal disease may be complicated 
by hyperkalemia because of decreased urinary 
potassium excretion from impaired glomerular 
filtration and/or a decline in aldosterone 
levels. The extent of renal impairment, the 
coadministration of drugs inhibiting kaliuresis 
and/or diabetes may also modulate serum 
potassium excretion in these patients.3
Hyperkalemia occurs in up to 10% of 
hospitalized patients, with 10% of those patients 
(i.e., up to 1% of hospitalized patients) having 
serum potassium greater than or equal to 6 
mmol/L.4 ACEI/ARB therapy is considered a 
contributing cause in 10% to 38% of hospitalized 
hyperkalemia cases.5 In ambulatory practice, 
ACEI/ARB therapy also contributes to 
hyperkalemia in up to 10% of patients3,6 with 
about 1% of patients with diabetes experiencing 
serious hyperkalemia.4 Furthermore, ACEI/ARB 
therapy is implicated in hyperkalemia in as many 
as 6% of patients enrolled in clinical trials.7
In Stockholm Creatinine Measurements 
(SCREAM) project with potassium monitoring 
in the year following ACE-I or ARB initiation 
(N=52 996) Potassium >5 mmol/L occurred 
in 5.6% (N=2977), potassium >5.5 mmol/L 
occurred in 1.7% (N=924), and potassium 
>6 mmol/L occurred in 0.63% (N=334). 
Hyperkalemia occurred much more frequently 
among people with lower eGFR. For example, 
among people with eGFR <30 mL/min per 1.73 
m2, new users of ACEI or ARB therapy had a 
55% and 29% 1-year occurrence of potassium 
>5 and >5.5 mmol/L, respectively.8
Concern about the limit of hyperkalemia after 
initiation of ACEI or ARB become important but 
the guideline which monitoring of potassium still 
unclear. Hyperkalemia with use of ACEI or ARB 
in chronic kidney disease will futher discuss.
CLASSIFICATION
Hyperkalemia can be classified according 
to serum potassium into mild (5.5–6.5 mmol/l), 
moderate (6.5–7.5 mmol/ l) and severe (>7.5 
mmol/l) hyperkalemia. Hyperkalemia not only 
rarely associated with symptoms, occasionally 
patients complain of palpitations, nausea, muscle 
pain, or paresthesia but also life threatening 
complications.9
CKD is defined as kidney damage or 
glomerular filtration rate (GFR) <60 mL/min/1.73 
m2 for 3 months or more, irrespective of cause. 
Kidney damage in many kidney diseases can 
be ascertained by the presence of albuminuria, 
defined as albumin-to-creatinine ratio >30 mg/g 
in two of three spot urine specimens. GFR can be 
estimated from calibrated serum creatinine and 
estimating equations, such as the Modification of 
Diet in Renal Disease (MDRD) Study equation 
or the Cockcroft-Gault formula 10. CKD could 
be classified according to severity, diagnosis, 
treatment and prognosis (Table 1).
PATHOPHYSIOLOGY
The renin – angiotensin - aldosterone system 
(RAAS) is a well known regulator of blood 
pressure (BP) and determinant of target organ 
damage. It controls fluid and electrolyte balance 
through coordinated effects on the heart, blood 
vessels, and Kidneys.11
ACE (also known as kininase II) is a relatively 
non-selective dipeptidyl carboxypeptidase that 
accepts various substrates, including angiotensin 
I and bradykinin. ACE catalyses the hydrolysis 
of bradykinin to inactive products and converts 
the inactive decapeptide angiotensin I to the 
biologically active octapeptide angiotensin 
II.12 Angiotensin II is the main effector of the 
RAAS and exerts its vasoconstrictor effect 
predominantly on the postglomerular arterioles, 
thereby increasing the glomerular hydraulic 
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pressure and the ultrafiltration of plasma 
proteins, effects that may contribute to the onset 
and progression of chronic renal damage.11 
Angiotensin II elevates blood pressure by various 
mechanisms, including direct vasoconstriction, 
potentiation of the activity of the sympathetic 
nervous system at both central and peripheral 
levels, stimulation of aldosterone synthesis 
and release with consequent sodium and fluid 
retention by the kidney, and stimulation of 
arginine vasopressin release.
Renin secretion is influenced by intra 
and extra renal factors such as low renal 
perfusion pressure, β-adrenergic stimulation, 
prostaglandins, angiotensin II, potassium, and 
sodium. Decreased sodium and chloride delivery 
to the distal tubule stimulate renin release. Renin 
acts on angiotensinogen in the blood to form 
angiotensin I, which is converted by angiotensin-
converting enzyme (ACE) to angiotensin 
II. Angiotensin II stimulates the release of 
aldosterone from zona glomerulosa cells in the 
adrenal cortex. Aldosterone secretion is also 
influenced by plasma potassium. Angiotensin II 
and potassium act synergistically on aldosterone 
release.
Aldosterone directly affects kidney potassium 
handling. Potassium secretion in the collecting 
duct is regulated primarily by serum aldosterone 
concentrations and the amount of sodium 
delivered to the distal nephron. Aldosterone 
binds to a receptor in collecting duct cells 
and stimulates sodium reabsorption across the 
luminal membrane through a sodium channel. 
As sodium is reabsorbed, the lumen becomes 
more electronegative and provides a favorable 
environment for potassium secretion through a 
potassium channel.7
Drugs acting on the RAAS include agents 
that inhibit renin synthesis and release; that is, 
the direct renin inhibitors and b-adrenoceptor 
blockers, the ACE inhibitors, the ARBs, the 
aldosterone-receptor antagonists (ARAs) and 
a new class of combined ACE and neutral 
endopeptidase (NEP) inhibitors, called the 
vasopeptidase inhibitors (VPIs). A total of 17 
ACE inhibitors have been developed for clinical 
use, and many have been approved for the 
treatment of hypertension, heart failure, diabetic 
nephropathy and/or left ventricular dysfunction. 
All ACE inhibitors act by binding to the active 
site of ACE and interfering with the ability of 
the enzyme to bind to and cleave its substrates, 
angiotensin I and bradykinin.
These compounds proved to be highly 
successful in the treatment of hypertension 
and related target-organ damage, including 
left ventricular hypertrophy, heart failure and 
post myocardial infarction left ventricular 
remodelling renal insufficiency and diabetes 
with proteinuria.
The ARBs are non-peptide compounds that 
specifically block the binding of angiotensin II to 
the AT1 receptor by occupying the space among 




treatmentGFR mL/min/1.73 m2 Related terms
1 Kidney damage with normal 
or  GFR > 90
Albuminuria, proteinuria, 
hematuria
T if kidney transplant 
recipient
2 Kidney damage with mild  GFR 60-89
Albuminuria, proteinuria, 
hematuria
3 Moderate  GFR 30-59 Chronic renal insufficiency, early renal insufficiency
4 Severe  GFR 15-29
Chronic renal insufficiency, 
late renal insufficiency, 
pre-ESRD
5 Kidney failure < 15 (or dialysis) Renal failure, uremia, end-
stage renal disease
D if dialysis (hemodialysis, 
peritoneal dialysis)
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the seven transmembrane helices of the receptor 
protein, and interacting with the amino-acid 
residues in this region of the receptor molecule. 
They do not interact with AT2 receptors. ARB 
administration indirectly activates the AT2 
receptor by blocking feedback inhibition of renin 
release and thereby activating the RAAS cascade 
and causing more angiotensin II to be generated, 
and shunting the angiotensin II so generated from 
AT1 to AT2 receptors.12
Under normal circumstances, there is 
an inverse relationship between the plasma 
aldosterone concentration and the delivery of 
sodium to the distal nephron so that potassium 
excretion remains independent of changes in 
extracellular fluid volume. Under conditions 
of decreased renal perfusion, aldosterone 
concentrations increase. At the same time, 
the proximal absorption of sodium and water 
increases, and as a result, their distal delivery 
decreases. Renal potassium excretion remains 
fairly constant under these conditions, since the 
stimulatory effect of increased aldosterone is 
counterbalanced by the decreased delivery of 
filtrate to the distal nephron.
Mild to moderate reductions in renal 
perfusion typically do not cause the distal delivery 
of sodium to fall to a level that impairs potassium 
secretion sufficiently to result in clinically 
significant hyperkalemia. In most patients with 
untreated congestive heart failure, the serum 
potassium concentration is normal or at the high 
end of the normal range as long as the impairment 
in cardiac function and renal perfusion is not 
severe. When such patients are treated with ACE 
inhibitors or angiotensin-receptor blockers, the 
fall in the circulating aldosterone concentration 
typically will be counterbalanced by increased 
distal delivery of sodium so that the serum 
potassium concentration remains stable. The 
increase in the distal delivery of sodium is 
due to the afterload-reducing effects of these 
drugs, which cause an improvement in cardiac 
output and renal perfusion. The reduction in 
angiotensin II concentration plays an important 
role in decreasing proximal sodium reabsorption. 
In addition, most patients are treated with loop 
diuretics, which further enhance the delivery of 
sodium to the collecting duct.
When renal perfusion becomes more severely 
reduced, as in intractable congestive heart failure, 
proximal reabsorption can become so intense that 
very little sodium escapes into the distal nephron. 
Despite increased concentrations of aldosterone, 
the lack of availability of sodium can begin to 
impair renal potassium secretion. To the extent 
that cardiac output and renal perfusion become 
refractory to the afterload-reducing effects of 
ACE inhibitors or angiotensin-receptor blockers, 
the risk of hyperkalemia increases. In this setting, 
these drugs may also cause the serum creatinine 
concentration to rise owing to reductions in 
intraglomerular pressure that are no longer offset 
by increases in glomerular perfusion.7
MANAGEMENT
The risk of severe complications and the 
urgency for treatment of hyperkalemia is 
determined by individual patient conditions 
including presenting symptoms, overall 
hemodynamic status, kidney function, underlying 
medical conditions, patient medications, rapidity 
of potassium rise, serum potassium level, acid-
base status, ECG findings, and so on.13
The initial approach to such a patient is to 
determine the specific risk of hyperkalemia by 
accurately assessing the level of renal function 
(Table 2).7
In patients with chronic kidney disease, the 
level of renal function should not be the sole 
criterion for deciding whether use of these drugs 
should be initiated or continued. When they are 
used in patients with severe reductions in the 
glomerular filtration rate (i.e., those with rates 
below 30 ml per minute), close monitoring is 
required. Withholding these drugs solely on 
the basis of the level of renal function will 
unnecessarily deprive many patients of the 
cardiovascular benefit that they otherwise would 
have received, particularly since numerous steps 
can be taken to minimize the risk of hyperkalemia.
Patients should follow a low-potassium diet 
with specific counseling against the use of salt 
substitutes that contain potassium. Diuretics are 
particularly effective in minimizing hyperkalemia. 
Diuretics enhance the excretion of potassium in 
the kidney by increasing the delivery of sodium to 
the collecting duct. In patients with an estimated 
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glomerular filtration rate that is 30 ml per minute 
or higher, thiazide diuretics can be used, but in 
patients with more severe renal insufficiency, loop 
diuretics are required.7
In patients with chronic kidney disease and 
metabolic acidosis, the administration of sodium 
bicarbonate is an effective strategy to minimize 
increases in the serum potassium concentration.14 
If treatment with an ACE inhibitor or an 
angiotensin-receptor blocker is to be initiated, 
it is best to begin with low doses. The serum 
potassium concentration should be checked 
within one week after the drug has been started. 
If the potassium con- centration is normal, then 
the dose of the drug can be titrated upward. With 
each increase in the dose, the serum potassium 
concentration should be measured again one 
week later.15
If the serum potassium concentration is 5.6 
mmol per liter or higher despite the precautions 
described above, then such drugs may need to 
be avoided. Particular attention should be given 
to patients with underlying disturbances of 
cardiac conduction, since even mild degrees of 
hyperkalemia can precipitate heart block.7
However, typical electrocardiography (ECG) 
changes in a patient with hyperkalemia, increases 
the urgency for treatment. The ‘‘classic’’ ECG 
changes associated with hyperkalemia are well 
described. The earliest changes, often beginning 
with levels above 6.5 mEq/L, are ‘‘peaked,’’ or 
‘‘tented’’ T-waves, which are most prominent in 
the precordial leads. With further rise in serum 
levels, there is diminished cardiac excitability 
manifested by flattening of the P-wave, PR interval 
lengthening, and the eventual disappearance of the 
P- wave. The QRS duration becomes prolonged, 
progressing to a ‘‘sine wave’’ appearance, and 
finally ending in ventricular asystole or fibrillation 
with levels 8 to 10 mmol/L.13
CONCLUSION
ACEI and ARB are effective therapeutic 
agents but can cause mild to life threatening 
hyperkalemia particularly in chronic kidney 
disease. To minimize the risk of hyperkalemia 
in patients initiate ACEI or ARB, filtration 
glomerular rate and serum potassium level must 
be estimated, drug that interfere in renal potassium 
secretion, potassium intake, supplements 
should be evaluated. If hyperkalemia occur, 
definitive treatment such as prevention of cardiac 
dysrhythmia and remove excess of potassium 
from the body can optimize the outcome.
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